Pharmacodynamics of empirical antibiotic monotherapies for an intensive care unit (ICU) population based on Canadian surveillance data

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 2, 2011, Pages 343-349

  Zelenitsky, Sheryl A ^a,b   Ariano, Robert E ^a,b   Zhanel, George G ^a,c  

^a UNIVERSITY OF MANITOBA   (Canada)

^b ST BONIFACE GENERAL HOSPITAL   (Canada)

^c HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Cefepime; Ceftobiprole; Meropenem; Monte Carlo simulation; Piperacillin tazobactam; Prolonged infusion

Indexed keywords

CEFEPIME; CEFTOBIPROLE; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM;

ANTIBIOTIC THERAPY; ARTICLE; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; ESCHERICHIA COLI; INTENSIVE CARE UNIT; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MONTE CARLO METHOD; NONHUMAN; PSEUDOMONAS AERUGINOSA;

ANTI-BACTERIAL AGENTS; CANADA; ESCHERICHIA COLI; HUMANS; INTENSIVE CARE UNITS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MONTE CARLO METHOD; PSEUDOMONAS AERUGINOSA;

EID: 78651438971     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq348     Document Type: Article

References (34)

1. Ambrose PG, Bhavnani SM, Rubino CM et al. Pharmacokineticspharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis 2007; 44: 79-86.
2. Drusano GL. Pharmacokinetics and pharmacodynamics of antimicrobials. Clin Infect Dis 2007; 45 Suppl 1: S89-95.
3. McKinnon PS, Yu VL. Pharmacologic considerations in antimicrobial therapy, with emphasis on pharmacokinetics and pharmacodynamics: reviews for the practicing clinician. Eur J Clin Microbiol Infect Dis 2004; 23: 231-2.
4. Pea F, Viale P, Furlanut M. Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet 2005; 44: 1009-34.
5. Roberts JA, Lipman J. Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Clin Pharmacokinet 2006; 45: 755-73.
6. Soy D, Torres A. Antibacterial dosage in intensive-care-unit patients based on pharmacokinetic/pharmacodynamic principles. Curr Opin Crit Care 2006; 12: 477-82.
7. DeRyke CA, Kuti JL, Nicolau DP. Reevaluation of current susceptibility breakpoints for Gram-negative rods based on pharmacodynamic assessment. Diagn Microbiol Infect Dis 2007; 58: 337-44.
8. Frei CR, Wiederhold NP, Burgess DS. Antimicrobial breakpoints for Gram-negative aerobic bacteria based on pharmacokineticpharmacodynamic models with Monte Carlo simulation. J Antimicrob Chemother 2008; 61: 621-8.
9. Turnidge J, Paterson DL. Setting and revising antibacterial susceptibility breakpoints. Clin Microbiol Rev 2007; 20: 391-408.
10. Zelenitsky S, Ariano R, Harding G et al. Evaluating ciprofloxacin dosing for Pseudomonas aeruginosa infection by using clinical outcome-based Monte Carlo simulations. Antimicrob Agents Chemother 2005; 49: 4009-14.
11. Li C, Kuti JL, Nightingale CH et al. Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection. J Antimicrob Chemother 2005; 56: 388-95.
12. Li C, Kuti JL, Nightingale CH et al. Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients. J Clin Pharmacol 2006; 46: 1171-8.
13. Lodise TP Jr, Pypstra R, Kahn JB et al. Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects. Antimicrob Agents Chemother 2007; 51: 2378-87.
14. Nicasio AM, Ariano RE, Zelenitsky SA et al. Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator-associated pneumonia. Antimicrob Agents Chemother 2009; 53: 1476-81.
15. Kimko H, Murthy B, Xu X et al. Population pharmacokinetic analysis of ceftobiprole for treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother 2009; 53: 1228-30.
16. Lodise TP Jr, Lomaestro B, Rodvold KA et al. Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation. Antimicrob Agents Chemother 2004; 48: 4718-24.
17. Roberts JA, Kirkpatrick CM, Roberts MS et al. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother 2009; 64: 142-50.
18. Tam VH, McKinnon PS, Akins RL et al. Pharmacodynamics of cefepime in patients with Gram-negative infections. J Antimicrob Chemother 2002; 50: 425-8.
19. Zhanel G, DeCorby M, Nichol K et al. Antimicrobial resistance in 13,163 pathogens from Canadian hospitals: CANWARD Study 2007 and 2008. In: Abstracts of the Forty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 2009. Abstract C2-1953, p. 148. American Society for Microbiology, Washington, DC, USA.
20. Zhanel G, Karlowsky JA, DeCorby M et al. Prevalence of antimicrobial-resistant pathogens in Canadian hospitals: results of the Canadian ward surveillance study (CANWARD 2007). Can J Infect Dis Med Microbiol 2009; 20: 9-19.
21. Zhanel GG, DeCorby M, Laing N et al. Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. Antimicrob Agents Chemother 2008; 52: 1430-7.
22. Zhanel GG, DeCorby M, Nichol KA et al. Antimicrobial susceptibility of 3931 organisms isolated from intensive care units in Canada: Canadian National Intensive Care Unit Study, 2005/2006. Diagn Microbiol Infect Dis 2008; 62: 67-80.
23. Li C, Du X, Kuti JL et al. Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimicrob Agents Chemother 2007; 51: 1725-30.
24. Ariano RE, Nyhlen A, Donnelly JP et al. Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia. Ann Pharmacother 2005; 39: 32-8.
25. Crandon JL, Bulik CC, Kuti JL et al. Clinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosa. Antimicrob Agents Chemother 2009; 54: 1111-6.
26. McKinnon PS, Paladino JA, Schentag JJ. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents 2008; 31: 345-51.
27. Noel G, Strauss R, Shah A et al. Ceftobiprole versus ceftazidime combined with linezolid for treatment of patients with nosocomial pneumonia. In: Abstracts of the Forty-eighth Interscience Conference on Antimicrobial Agents and Chemotherapy/Forty-sixth Infectious Diseases Society of America Annual Meeting, Washington, DC, 2008. Abstract K-486, p. 444. American Society for Microbiology, Washington, DC, USA/Infectious Diseases Society of America, Arlington, VA, USA.
28. Bhat SV, Peleg AY, Lodise TP Jr et al. Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by gram-negative organisms. Antimicrob Agents Chemother 2007; 51: 4390-5.
29. Kuti JL, Dandekar PK, Nightingale CH et al. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem. J Clin Pharmacol 2003; 43: 1116-23.
30. Tam VH, Gamez EA, Weston JS et al. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint. Clin Infect Dis 2008; 46: 862-7.
31. Lodise TP Jr, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 2007; 44: 357-63.
32. Fuster-Lluch O, Geronimo-Pardo M, Peyro-Garcia R et al. Glomerular hyperfiltration and albuminuria in critically ill patients. Anaesth Intensive Care 2008; 36: 674-80.
33. Pea F, Furlanut M, Viale P. Is antimicrobial underexposure due to glomerular hyperfiltration a possible cause of increased mortality rate from bacterial infections in critically ill patients? Anaesth Intensive Care 2009; 37: 323-4.
34. Udy AA, Roberts JA, Boots RJ et al. Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin Pharmacokinet 2010; 49: 1-16.